Stock Track | Burning Rock Biotech Soars 7.61% Intraday as Breast Cancer Diagnostic Kit Enters Priority Review

Stock Track01-26

Burning Rock Biotech Limited's stock soared 7.61% during intraday trading on Monday, following positive regulatory news for the company's diagnostic pipeline.

The surge came after the company announced that its self-developed "OncoScreen® BCMatch Tissue Kit," a breast cancer next-generation sequencing companion diagnostic kit, has entered the Priority Review Channel of China's Center for Medical Device Evaluation. This marks the first breast cancer NGS CDx kit in China to enter this expedited review process, which is expected to accelerate its domestic approval timeline.

This regulatory milestone represents significant progress for Burning Rock Biotech's oncology diagnostics portfolio and could potentially enhance the company's market position in China's growing precision medicine landscape.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136963079?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-26 23:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136963079","market":"nz","top_or_hot":-1,"title":"Stock Track | Burning Rock Biotech Soars 7.61% Intraday as Breast Cancer Diagnostic Kit Enters Priority Review","media":"Stock Track","content":"<p>Burning Rock Biotech Limited's stock soared 7.61% during intraday trading on Monday, following positive regulatory news for the company's diagnostic pipeline.</p><p>The surge came after the company announced that its self-developed \"OncoScreen® BCMatch Tissue Kit,\" a breast cancer next-generation sequencing companion diagnostic kit, has entered the Priority Review Channel of China's Center for Medical Device Evaluation. This marks the first breast cancer NGS CDx kit in China to enter this expedited review process, which is expected to accelerate its domestic approval timeline.</p><p>This regulatory milestone represents significant progress for Burning Rock Biotech's oncology diagnostics portfolio and could potentially enhance the company's market position in China's growing precision medicine landscape.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Burning Rock Biotech Soars 7.61% Intraday as Breast Cancer Diagnostic Kit Enters Priority Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Burning Rock Biotech Soars 7.61% Intraday as Breast Cancer Diagnostic Kit Enters Priority Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-26 23:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Burning Rock Biotech Limited's stock soared 7.61% during intraday trading on Monday, following positive regulatory news for the company's diagnostic pipeline.</p><p>The surge came after the company announced that its self-developed \"OncoScreen® BCMatch Tissue Kit,\" a breast cancer next-generation sequencing companion diagnostic kit, has entered the Priority Review Channel of China's Center for Medical Device Evaluation. This marks the first breast cancer NGS CDx kit in China to enter this expedited review process, which is expected to accelerate its domestic approval timeline.</p><p>This regulatory milestone represents significant progress for Burning Rock Biotech's oncology diagnostics portfolio and could potentially enhance the company's market position in China's growing precision medicine landscape.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNR","symbol_name":"燃石医学","start_time":0,"source_url":"","article_id":"1136963079","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136963079","pubTimestamp":1769440587,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Burning Rock Biotech Limited's stock soared 7.61% during intraday trading on Monday, following positive regulatory news for the company's diagnostic pipeline.The surge came after the company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNR":"燃石医学"},"translate_title":"个股追踪|燃石生物盘中大涨7.61%乳腺癌诊断试剂盒进入优先审评","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNR":1},"content_text":"Burning Rock Biotech Limited's stock soared 7.61% during intraday trading on Monday, following positive regulatory news for the company's diagnostic pipeline.The surge came after the company announced that its self-developed \"OncoScreen® BCMatch Tissue Kit,\" a breast cancer next-generation sequencing companion diagnostic kit, has entered the Priority Review Channel of China's Center for Medical Device Evaluation. This marks the first breast cancer NGS CDx kit in China to enter this expedited review process, which is expected to accelerate its domestic approval timeline.This regulatory milestone represents significant progress for Burning Rock Biotech's oncology diagnostics portfolio and could potentially enhance the company's market position in China's growing precision medicine landscape.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136963079","isCrawlerRequest":true}